Objective To observe the efficacy and safety of lobaplatin(LBP) combined with etoposide or irinotecan for patients with advanced small cell lung cancer(SCLC).Methods Forty-five patients with histologically diagnosed SCLC were divided into two groups.The LE regimen group(lobaplatin 30mg/m2 iv d1,VP-16 100mg iv d1-d3,21 days were a cycle) had 25 patients and the LI regimen group(lobaplatin 30mg/m2 iv d1,irinotecan 60 mg/m2 iv d1,d8,d15,28 days were a cycle) had 20 patients.The efficacy and toxicity were evaluated after at least two cycles of chemotherapy.Results Forty-five patients were evaluable for response,in which 2 achieved complete response(CR),24 partial responses(PR),and the response rate(RR) was 57.8%.The RR in LE regimen group was 48.0%(12/25),while in LI regimen group was 70.0%(14/20).The median overall survival(OS) of LE regimen and LI regimen were 8.0 months and 7.0 months,respectively(P=0.255).The main toxicities were reversible bone marrow suppression and gastrointestinal reaction.Grade 3-4 thrombocytopenia rate was 17.8%(8/45),the occurence rate was higher in LI regimen than LE regimen(30.0% vs.8.0%,P=0.002).All grade 3-4 diarrhea was all occurred in patients with LI regimen(8.9%,4/45),who were retreated patints too.There was no treatment-related death.Conclusion Lobaplatin combined with etoposide or irinotecan is effective and tolerated for patients with advanced small cell lung cancer,and worth further study.